Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?

Orson W. Moe, Makoto Kuro-O

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

Original languageEnglish (US)
Pages (from-to)1022-1023
Number of pages2
JournalKidney International
Volume85
Issue number5
DOIs
StatePublished - 2014

Fingerprint

Vascular Calcification
Biomarkers
Chronic Renal Insufficiency
Theoretical Models
Cell Culture Techniques
fibroblast growth factor 23

ASJC Scopus subject areas

  • Nephrology
  • Medicine(all)

Cite this

Fibroblast growth factor 23 and uremic vascular calcification : Is it time to escalate from biomarker status to pathogenic agent? / Moe, Orson W.; Kuro-O, Makoto.

In: Kidney International, Vol. 85, No. 5, 2014, p. 1022-1023.

Research output: Contribution to journalArticle

@article{ffd985339b51497dab4059f467d8ec22,
title = "Fibroblast growth factor 23 and uremic vascular calcification: Is it time to escalate from biomarker status to pathogenic agent?",
abstract = "Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.",
author = "Moe, {Orson W.} and Makoto Kuro-O",
year = "2014",
doi = "10.1038/ki.2013.471",
language = "English (US)",
volume = "85",
pages = "1022--1023",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Fibroblast growth factor 23 and uremic vascular calcification

T2 - Is it time to escalate from biomarker status to pathogenic agent?

AU - Moe, Orson W.

AU - Kuro-O, Makoto

PY - 2014

Y1 - 2014

N2 - Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

AB - Although epidemiologic associations have been informative, the elucidation of the role of fibroblast growth factor 23 (FGF23) in chronic kidney disease (CKD) requires testing with robust experimental models. Jimbo et al. used animal and cell-culture models to query whether FGF23 is a direct 'vasculotoxin.' We discuss the interpretation of their findings. At this juncture, much remains unanswered about the significance of FGF23 elevation in CKD.

UR - http://www.scopus.com/inward/record.url?scp=84899708905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84899708905&partnerID=8YFLogxK

U2 - 10.1038/ki.2013.471

DO - 10.1038/ki.2013.471

M3 - Article

C2 - 24786878

AN - SCOPUS:84899708905

VL - 85

SP - 1022

EP - 1023

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 5

ER -